Investing.com – Gilead Sciences stock (NASDAQ: GILD ) fell more than 4% Friday as the maker of remdesivir said sales of non-Covid drugs would be lower in 2021 than earlier forecast.
The company said the pandemic is affecting its business longer than it expected to and was thus lowering its expectations from sales of non-Covid drugs. Excluding Veklury, the brand name Gilead uses to market its patented Covid treatment remdesivir, total product sales are seen around $21.5 billion, lower than the midpoint $21.8 billion it saw earlier.
Sales of Veklury are seen higher now, and the company thus raised its overall outlook.
The company now sees total product sales at $26.15 billion compared to the previous forecast of $24.7 billion.
Gilead now expects to repay $4.75 billion of debt this year, significantly exceeding its prior guidance or paying down at least $4 billion.
Robust sales of remdesivir, arguably one of the few drugs effective against the virus, propelled its third-quarter sales by 13%, to $7.4 billion.
Adjusted profit share was $2.65, higher than last time’s $2.11. Both sales and profit beat estimates.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.